vs
Side-by-side financial comparison of GILAT SATELLITE NETWORKS LTD (GILT) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
GILAT SATELLITE NETWORKS LTD is the larger business by last-quarter revenue ($152.7M vs $129.7M, roughly 1.2× Travere Therapeutics, Inc.).
Gilat Satellite Networks Ltd. is an Israeli public company. It provides satellite-based broadband communications technology, its main expertise being the development, manufacture, and marketing of ground-based satellite systems for global communication via satellites.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
GILT vs TVTX — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $152.7M | $129.7M |
| Net Profit | $6.3M | — |
| Gross Margin | 35.8% | 98.0% |
| Operating Margin | 5.4% | -25.0% |
| Net Margin | 4.1% | — |
| Revenue YoY | — | 73.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $57016808.00 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $129.7M | ||
| Q3 25 | — | $164.9M | ||
| Q2 25 | $152.7M | $114.4M | ||
| Q1 25 | — | $81.7M | ||
| Q4 24 | — | $74.8M | ||
| Q3 24 | — | $62.9M | ||
| Q2 24 | $126.6M | $54.1M | ||
| Q1 24 | — | $41.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | $25.7M | ||
| Q2 25 | $6.3M | $-12.8M | ||
| Q1 25 | — | $-41.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-54.8M | ||
| Q2 24 | $9.9M | $-70.4M | ||
| Q1 24 | — | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | 35.8% | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | 39.7% | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | — | -25.0% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | 5.4% | -11.1% | ||
| Q1 25 | — | -52.2% | ||
| Q4 24 | — | -81.2% | ||
| Q3 24 | — | -89.3% | ||
| Q2 24 | 9.8% | -125.1% | ||
| Q1 24 | — | -336.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 15.6% | ||
| Q2 25 | 4.1% | -11.1% | ||
| Q1 25 | — | -50.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -87.1% | ||
| Q2 24 | 7.8% | -130.1% | ||
| Q1 24 | — | -328.9% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | — | $0.28 | ||
| Q2 25 | $57016808.00 | $-0.14 | ||
| Q1 25 | — | $-0.47 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.70 | ||
| Q2 24 | $56622204.00 | $-0.91 | ||
| Q1 24 | — | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.9M | $93.0M |
| Total DebtLower is stronger | $56.5M | — |
| Stockholders' EquityBook value | $315.8M | $114.8M |
| Total Assets | $575.9M | $605.2M |
| Debt / EquityLower = less leverage | 0.18× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.0M | ||
| Q3 25 | — | $110.9M | ||
| Q2 25 | $64.9M | $75.2M | ||
| Q1 25 | — | $61.9M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | $93.7M | $32.3M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $56.5M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $114.8M | ||
| Q3 25 | — | $73.6M | ||
| Q2 25 | $315.8M | $32.7M | ||
| Q1 25 | — | $32.8M | ||
| Q4 24 | — | $59.1M | ||
| Q3 24 | — | $-30.5M | ||
| Q2 24 | $282.8M | $15.1M | ||
| Q1 24 | — | $74.1M |
| Q4 25 | — | $605.2M | ||
| Q3 25 | — | $538.6M | ||
| Q2 25 | $575.9M | $555.3M | ||
| Q1 25 | — | $548.8M | ||
| Q4 24 | — | $594.1M | ||
| Q3 24 | — | $504.4M | ||
| Q2 24 | $416.9M | $551.1M | ||
| Q1 24 | — | $663.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $60.7M | ||
| Q3 25 | — | $14.3M | ||
| Q2 25 | — | $5.0M | ||
| Q1 25 | — | $-42.2M | ||
| Q4 24 | — | $-35.7M | ||
| Q3 24 | — | $-42.5M | ||
| Q2 24 | $8.2M | $-40.2M | ||
| Q1 24 | — | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.7M | $-40.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.3% | -74.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | 5.2% | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.83× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILT
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
